Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28766847 | 0.79 | GLB1 (0.37) | ALDH1A1DRD3MAPK1 | |
| SCHEMBL14940873 | 0.78 | MEN1 (0.33) | DRD3 | |
| SCHEMBL14941197 | 0.78 | DRD3 (0.38) | DRD3 | |
| SCHEMBL28155137 | 0.77 | PDK1 (0.31) | — | |
| SCHEMBL28134274 | 0.76 | KDM4E (0.45) | KDM4EALDH1A1DRD3SLC18A3MAPK1 | |
| SCHEMBL28199158 | 0.73 | ALDH1A1 (0.42) | KDM4EALDH1A1DRD3SLC18A3MAPK1 | |
| SCHEMBL4192102 | 0.72 | ALDH1A1 (0.39) | KDM4EALDH1A1DRD3SLC18A3MAPK1 | |
| SCHEMBL4634683 | 0.72 | KDM4E (0.45) | KDM4EALDH1A1DRD3SLC18A3MAPK1 | |
| SCHEMBL12331468 | 0.72 | KDM4E (0.45) | KDM4EALDH1A1DRD3SLC18A3MAPK1 | |
| SCHEMBL6043875 | 0.72 | KDM1A (0.47) | KDM4EALDH1A1DRD3SLC18A3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | disclosed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | disclosed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | KDM4E 4459/4885ALDH1A1 2797/4885DRD3 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.